Amgen stock holds above $417 as Q2 2026 beats drive higher guidance
Published on 08/14/2026 at 08:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen Inc. (ISIN US0311621009) stock is holding above the $417 mark following a strong second quarter 2026 earnings performance and an increase to full-year guidance that underscores the company’s momentum as of August 13, 2026. Per a recent earnings overview, Amgen reported double-digit revenue growth, raised its 2026 sales and earnings targets, and highlighted obesity candidate MariTide as a central pillar of its long-term strategy.
Q2 2026 earnings beat and guidance raise
For the second quarter of calendar 2026, Amgen delivered revenue of $10.05 billion, exceeding analyst estimates of $9.40 billion and representing 9.5% year-on-year growth in the latest reporting period. A related summary of the quarter notes that adjusted earnings per share reached $6.29 versus expectations of $5.62, implying a 12% beat relative to consensus and reflecting the profitability of the company’s portfolio at this stage.
Management indicated that operating performance improved notably, with adjusted operating income of $4.61 billion against analyst estimates of $4.15 billion, corresponding to a margin of 45.9% and an 11.1% beat versus the forecast for the quarter. In addition, Amgen’s operating margin for the period was reported at 35%, compared with 28.9% in the same quarter of the prior year, underscoring significant leverage as newer therapies scale.
On the earnings call dated August 4, 2026, Amgen’s leadership outlined an updated full-year outlook that reflects this momentum. An earnings recap shows that management now expects 2026 total revenues in the range of $38.2 billion to $39.4 billion, with the midpoint of $38.8 billion representing an increase from a prior midpoint of $37.8 billion. The same overview notes that non-GAAP earnings per share guidance has been raised to a band of $22.30 to $23.50, with another source highlighting a midpoint of $22.90 as the new anchor for investor expectations.
The guidance revisions provide a clear quantified comparison for investors: the revenue midpoint is higher by $1.0 billion and the EPS midpoint is higher by $0.50 versus the company’s previous outlook. These changes signal confidence in demand for key growth drivers and suggest that the second half of 2026 is set to build on the strong first half.
Beyond headline numbers, management emphasized portfolio breadth. One detailed Q2 2026 analysis notes that 22 products achieved double-digit sales growth and 17 products had annualized sales above $1 billion, helping Amgen navigate patent expirations and competitive pressures while sustaining overall top-line growth. This breadth matters for investors evaluating durability of earnings and cash flows beyond 2026.
Capital allocation, costs and obesity investments
Alongside higher guidance, Amgen’s second-quarter commentary highlighted a series of capital allocation and investment decisions that shape its financial profile. A transcript of the Q2 2026 earnings call states that research and development expenses reached $1.85 billion on a non-GAAP basis in the quarter, marking a 10% increase year over year as the company supports nine ongoing Phase 3 trials for obesity candidate MariTide. For investors, this level of R&D spending is a meaningful number because it balances current profitability with long-term pipeline expansion.
The same call documentation indicates that Amgen plans capital expenditures of $2.6 billion for the full year 2026, directed toward expanding manufacturing capacity for weight management products and other growth areas. Management further expects other revenue to be approximately $1.9 billion in 2026, implying a diversified set of income streams beyond core product sales.
From a shareholder return perspective, Amgen continues to return cash through dividends and repurchases. An earnings summary notes that the company paid dividends of $2.52 per share in the second quarter of 2026, representing a 6% increase compared with the second quarter of 2025. It also reiterates that planned share repurchases for the full fiscal year are not expected to exceed $3.0 billion, providing a quantified ceiling for buyback activity that investors can factor into their valuation models.
Tax and cost structure guidance was also clarified. According to the same call coverage, Amgen expects a non-GAAP tax rate in the range of 15.0% to 16.5% for 2026, which helps analysts refine net income and EPS projections. Taken together, higher revenue and EPS guidance, elevated R&D spending, and constrained buybacks paint a picture of a large-cap biopharma company prioritizing pipeline investment while maintaining shareholder payouts.
Current trading levels and technical snapshot
On the market side, Amgen stock remains supported by this fundamental backdrop. A dedicated market-data page shows that Amgen closed at $417.99 on August 13, 2026, equivalent to a gain of $1.81 or 0.43% for that trading session, with quotes delayed by 15 minutes. Another real-time trends overview lists the same closing price of $417.99 and confirms the ticker symbol AMGN, highlighting that this level is consistent across intraday snapshots.
A complementary news feed focused on Amgen notes that the stock closed at $417.84 on August 13, 2026, up $1.66 or 0.40% at 4:00 p.m. Eastern time, with extended trading bringing the price to $418.00 as of 5:59 p.m. Eastern. While these pages report marginal differences in the penny-level closing figure, they collectively point to Amgen trading a little above $417 per share as of the latest completed regular session.
Technical analysis adds another dimension. A chart-based overview lists a recent Amgen price of $417.99 with a daily move of 0.43% on August 13, 2026, and characterizes the current short-term signal based on moving averages and indicators as Neutral. This suggests that, at least by those tools, the share price is consolidating rather than showing a strong directional push, giving investors time to digest earnings and guidance data.
Market capitalization figures reflect Amgen’s scale at these price levels. A focused Q2 recap reports a market value of $225.6 billion associated with Amgen’s recent trading range, while a separate market portal lists a market cap of $225.97 billion, implying that shifts in the share price are moving overall equity value modestly around the $226 billion mark. These numbers place Amgen firmly among the largest global biopharmaceutical companies and help contextualize its role in major equity indices.
In addition, institutional ownership statistics demonstrate the breadth of professional participation in the stock. One institutional holdings overview notes that as of the first quarter of 2026, 4,665 institutions held shares of Amgen with a combined market value of $460.83 million, accounting for 85.38% of the total shares. Even though this figure focuses on one subset of institutional positions, it underlines that a substantial portion of Amgen’s float is held by professional investors, which can influence liquidity and trading behavior.
Analyst stance and price targets
Beyond pure market data, recent coverage sheds light on how analysts view Amgen at current levels. A rating summary states that the stock presently has an average rating of Hold and an average price target of $371.68 according to compiled analyst data, implying that the consensus target sits below the current price of just over $417 per share. This gap gives investors a quantified comparison between the market’s valuation and the street’s aggregate expectations.
Another market-data result notes that Amgen carries an overall signal of signal_hold, paired with a reported analyst price objective of $383.24. This figure is closer to the current trading level than the broader average mentioned above yet still below the latest closing price, indicating a cautious stance as analysts weigh strong near-term performance against competition and pipeline risk.
Insider activity has also been documented. A recent insider-transaction alert reports that shares of Amgen traded at $417.84 during regular hours on August 13, 2026, in the context of a senior vice president selling stock valued at $825,140. While single insider sales can have various motivations, the combination of insider transactions, a Hold consensus, and price targets below the current market level reinforces the picture of a stock priced for robust expectations.
For investors, the key takeaway from this analyst and insider data is that Amgen’s share price already reflects a fair amount of optimism about future growth. With Q2 2026 results beating forecasts and guidance moving higher, the question becomes whether continued execution, especially in obesity and other high-growth segments, can justify trading sustainably above the average target range.
MariTide and obesity portfolio ambitions
Strategically, Amgen is investing heavily in obesity and weight management, positioning its candidate MariTide as a flagship program. The Q2 2026 earnings call materials state that there are nine ongoing Phase 3 trials for MariTide, backed by higher R&D spending and a planned 2026 capital expenditure budget of $2.6 billion to expand manufacturing capacity for weight management products.
Management commentary in the same transcript underscores that capital expenditures in 2026 are expected to be approximately $2.6 billion, specifically to scale manufacturing capacity for volume growth tied to obesity launches, including MariTide. The emphasis on capacity expansion indicates that the company is planning for significant demand if regulatory and commercial milestones are achieved.
Amgen’s portfolio of six key growth drivers, which together account for nearly 70% of total product sales according to the call materials, provides context for the potential role of MariTide. Growth brands in cardiovascular and respiratory indications showed double-digit performance in Q2 2026, helping fuel the 9.5% revenue increase and underlying the raised guidance. MariTide is expected to complement these franchises by tapping into the global obesity market, which many investors view as a multi-year secular opportunity.
From a product-level perspective, Amgen is balancing the build-out of MariTide with continued support for existing biologics and small-molecule therapies. The nine Phase 3 studies highlighted on the call represent a sizable late-stage pipeline commitment, and the associated R&D and capital expenditures integrate with the broader financial picture discussed earlier.
For investors analyzing Amgen’s stock at current levels, the MariTide program is central to long-term growth assumptions. The combination of raised 2026 guidance, boosted R&D, and explicit manufacturing expansion plans suggests that management is willing to invest heavily to capture future revenue streams in obesity while maintaining double-digit earnings power in the near term.
Dividend, buybacks and balance between growth and returns
Income-oriented investors often look closely at Amgen’s dividend and buyback policy, and the latest quarter provided fresh data points. The Q2 2026 call transcript indicates that the dividend for the quarter was $2.52 per share, which is 6% higher than the payout in the second quarter of 2025. This quantified increase points to a continued commitment to progressive shareholder returns even as investment demands grow.
The same materials spell out a cap on share repurchases, with management expecting buybacks not to exceed $3.0 billion in 2026. Given Amgen’s market capitalization in the area of $226 billion, this ceiling represents a modest percentage of the company’s equity value, suggesting that repurchases are designed as a stabilizing and accretive capital return tool rather than a primary lever for EPS growth.
Balancing these cash returns, Amgen’s plan for 2026 capital expenditures of $2.6 billion and elevated R&D spending of $1.85 billion in Q2 2026 point to a substantial allocation toward internal growth and capacity-building. For investors, the critical interpretation is that Amgen is attempting to strike a balance between increasing its dividend, maintaining buybacks within a defined limit, and funding the obesity and broader pipeline agenda through significant reinvestment.
This balance will be important to monitor as more data from MariTide’s Phase 3 program and other trials emerge. If clinical and commercial milestones support the current trajectory of guidance, dividend growth and controlled buybacks may continue alongside further spending on manufacturing and R&D. Conversely, any setbacks could lead management to revisit the mix of capital allocation priorities.
Representative product focus: MariTide obesity candidate
MariTide, Amgen’s key obesity candidate, is a central element of the company’s strategy and a representative product for understanding how its pipeline could reshape future financials. The Q2 2026 earnings call documentation highlights that nine Phase 3 trials are underway for MariTide, demonstrating a broad clinical program aimed at characterizing efficacy and safety across multiple patient populations and potentially different dosing regimens.
The focus on MariTide ties directly to Amgen’s 2026 capital expenditures, with management stating that the planned $2.6 billion for the year will be used to expand manufacturing capacity for volume growth, including for weight management launches like MariTide. This investment in physical capacity complements elevated R&D spending and positions the company to scale quickly if regulatory approvals are secured.
For retail investors, the key point is that MariTide could become a major growth driver if clinical trial data support robust efficacy and tolerability, and if payer and physician adoption follows. Given that six existing growth drivers already contribute nearly 70% of total product sales, the addition of a successful obesity franchise could reinforce Amgen’s ability to sustain or expand its raised revenue guidance range of $38.2 billion to $39.4 billion.
However, obesity is a competitive space, and Amgen’s commitment of nine Phase 3 trials underscores both the opportunity and the need to differentiate its offering. Investor attention is likely to focus on upcoming data releases and regulatory interactions for MariTide over the next several quarters, particularly in light of the elevated spending and capacity expansion numbers disclosed for 2026.
Closing view on Amgen stock and current price snapshot
Amgen stock is trading just above $417 per share based on the latest completed regular session, with a market-data page reporting a closing price of $417.99 on August 13, 2026, and a news overview listing a close of $417.84 with extended trading at $418.00 on the same date. These figures, combined with a market capitalization of roughly $226 billion and an analyst average price target in the low to mid $370s, frame the current valuation environment for the shares.
For investors evaluating Amgen today, the combination of a Q2 2026 revenue beat to $10.05 billion, raised full-year guidance to a revenue midpoint of $38.8 billion and an EPS midpoint around $22.90, and substantial obesity-focused investment via MariTide suggests a company balancing near-term earnings strength with long-term pipeline risk. The Neutral technical signal and Hold consensus provide a measured backdrop, making future data from MariTide and continued delivery against 2026 guidance key to the next phase of Amgen’s stock story.
Go deeper
Read more on Amgen stock, including detailed earnings commentary and updated guidance figures, in the latest Q2 2026 earnings call transcript and related investor materials.
Investor Relations
Further information on Amgen Inc., including corporate governance, pipeline details and financial reports, is available from the company’s investor relations resources.
Fact box
Company: Amgen Inc.
ISIN: US0311621009
Ticker: AMGN
Exchange: Nasdaq
Price (as of August 13, 2026, 4:00 p.m. ET): $417.84 USD
Market cap: $225.97 billion (as of August 13, 2026)
Sector / Industry: Health Care / Biotechnology
Index membership: S&P 500
